By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751



Company News
Sarepta (SRPT) Announces Proposed Public Offering Of Common Stock 10/6/2015 12:03:38 PM
Sarepta (SRPT) Announces Pricing Of $127 Million Public Offering Of Common Stock 10/6/2015 10:52:08 AM
Sarepta (SRPT) Announces Collaborative Research Agreement With Murdoch University Researchers Steve Wilton and Sue Fletcher 10/2/2015 10:24:48 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/1/2015 12:55:57 PM
Sarepta (SRPT) Announces Additional Long-Term Efficacy And Safety Data From Pivotal Phase IIb Program Of Eteplirsen For Treatment Of Duchenne Muscular Dystrophy 10/1/2015 11:37:58 AM
Sarepta (SRPT) Announces Appointment Of Jean-Paul Kress, M.D. To The Company‚Äôs Board Of Directors 10/1/2015 9:09:46 AM
Strong Data Shows that Cambridge's Sarepta (SRPT) May Earn Approval of Duchenne Drug 10/1/2015 6:26:21 AM
Sarepta (SRPT) Announces USPTO Decision In Patent Interference Case With BioMarin (BMRN) 9/30/2015 12:15:43 PM
Sarepta (SRPT) Announces Corporate Update And Report On Recent Data From Phase Iib Study Of Eteplirsen For Duchenne Muscular Dystrophy 9/25/2015 8:43:12 AM
Sarepta (SRPT) To Present Company Overview At The 2015 Morgan Stanley (MST) Global Healthcare Conference 9/10/2015 11:13:42 AM